文献速递肿瘤 PET/CT

18F-FDG PET中病灶SUV与病灶SUR的重测变异性:两项前瞻性多中心试验数据分析

Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials.
PubMed 文献 · J Nucl Med · 2017-05-04

本研究基于两项前瞻性多中心试验(ACRIN 6678和MK-0646-008)共73例晚期非小细胞肺癌患者,在治疗前不同天进行两次18F-FDG PET/CT显像,评估病灶SUVmax、SUVpeak及肿瘤-血液SUV比值(SUR)的重测变异性(TRV)。结果显示SUV的TRV为32.1,SUR的TRV为29.0,SUR相对SUV的TRV降低因子为0.9;亚组分析显示当血液SUV与摄取时间变异增大时,SUR对TRV的降低作用更明显(δCFmin=20%亚组RTRV≈0.4)。

要点

  • 研究纳入73例晚期非小细胞肺癌患者,两次PET/CT间隔3.6±2.1天(范围1-7天)。
  • SUV的TRV为32.1,SUR的TRV为29.0,SUR相对SUV的TRV降低因子为0.9。
  • δCFmin=20%亚组RTRV≈0.4,SUR的TRV较SUV降低超过2倍。

核心结论

  • 血液SUV和摄取时间的变异是病灶SUV重测变异性的因果因素,用SUR替代SUV作为摄取指标可降低病灶摄取的TRV。
  • 在临床典型观察到的血液SUV和摄取时间变异水平下,这种改善变得显著。

研究设计与样本

  • 研究纳入来自前瞻性多中心试验ACRIN 6678(n=34)和MK-0646-008(n=39)的73例晚期非小细胞肺癌患者。
  • 所有患者在治疗前不同天接受两次18F-FDG PET/CT检查,时间差为3.6±2.1天(范围1-7天)。
  • 每例患者评估最多7个肿瘤病灶,测定SUVmax和SUVpeak,血液SUV取衰减CT图像上勾画并转移至PET图像的三维主动脉感兴趣区的均值。
  • SUR计算为肿瘤SUV与血液SUV的比值,并经摄取时间校正至注射后75分钟。
  • TRV量化为1.96乘以SUV和SUR配对分数差异的均方根偏差。

主要发现

  • 组平均TRVSUV为32.1,TRVSUR为29.0,对应SUR相对SUV的TRV降低因子RTRV为0.9。
  • 亚组分析显示RTRV与δCFmean呈显著负相关(Spearman ρ=-0.99,P<0.001)。
  • 在δCFmin=20%亚组中RTRV≈0.4,对应TRVSUR较TRVSUV降低超过2倍。

关键数值与推荐

  • TRV定义为1.96乘以配对分数差异的均方根偏差。
  • SUR为肿瘤SUV与血液SUV的比值,摄取时间校正至注射后75分钟。
  • RTRV定义为TRVSUR/TRVSUV,反映SUR相对SUV的TRV降低程度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quantitative assessment of radio- and chemotherapy response with 18F-FDG whole-body PET has attracted increasing interest in recent years. In most published work, SUV has been used for this purpose. In the context of therapy response assessment, the reliability of lesion SUVs, notably their test-retest stability, thus becomes crucial. However, a recent study demonstrated substantial test-retest variability (TRV) in SUVs. The purpose of the present study was to investigate whether the tumor-to-blood SUV ratio (SUR) can improve TRV in tracer uptake. Methods: 73 patients with advanced non-small cell lung cancer from the prospective multicenter trials ACRIN 6678 (n = 34) and MK-0646-008 (n = 39) were included in this study. All patients underwent two 18F-FDG PET/CT investigations on two different days (time difference, 3.6 ± 2.1 d; range, 1-7 d) before therapy. For each patient, up to 7 tumor lesions were evaluated. For each lesion, SUVmax and SUVpeak were determined. Blood SUV was determined as the mean value of a 3-dimensional aortic region of interest that was delineated on the attenuation CT image and transferred to the PET image. SURs were computed as the ratio of tumor SUV to blood SUV and were uptake time-corrected to 75 min after injection. TRV was quantified as 1.96 multiplied by the root-mean-square deviation of the fractional paired differences in SUV and SUR. The combined effect of blood normalization and uptake time correction was inspected by considering RTRV (TRVSUR/TRVSUV), a ratio reflecting the reduction in the TRV in SUR relative to SUV. RTRV was correlated with the group-averaged-value difference (δ) in CFmean (δCFmean) of the quantity δCF = |CF - 1|, where CF is the numeric factor that converts individual ratios of paired SUVs into corresponding SURs. This correlation analysis was performed by successively increasing a threshold value δCFmin and computing δCFmean and RTRV for the remaining subgroup of patients/lesions with δCF ≥ δCFminResults: The group-averaged TRVSUV and TRVSUR were 32.1 and 29.0, respectively, which correspond to a reduction of variability in SUR by an RTRV factor of 0.9 in comparison to SUV. This rather marginal improvement can be understood to be a consequence of the atypically low intrasubject variability in blood SUV and uptake time and the accordingly small δCF values in the investigated prospective study groups. In fact, subgroup analysis with increasing δCFmin thresholds revealed a pronounced negative correlation (Spearman ρ = -0.99, P < 0.001) between RTRV and δCFmean, where RTRV ≈ 0.4 in the δCFmin = 20% subgroup, corresponding to a more than 2-fold reduction of TRVSUR compared with TRVSUVConclusion: Variability in blood SUV and uptake time has been identified as a causal factor in the TRV in lesion SUV. Therefore, TRV in lesion uptake measurements can be reduced by replacing SUV with SUR as the uptake measure. The improvement becomes substantial for the level of variability in blood SUV and uptake time typically observed in the clinical context.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hofheinz F, Apostolova I, Oehme L, et al. Test-Retest Variability in Lesion SUV and Lesion SUR in 18F-FDG PET: An Analysis of Data from Two Prospective Multicenter Trials. J Nucl Med. 2017. PMID: 28473598. doi:10.2967/jnumed.117.190736

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。